Interestingly, several studies have shown that treatment of mice or rats with CL316,243 or other β3-AR-selective agonists causes anti-obesity and antidiabetic effects similar to those described here for CNO-treated adipo-GsD mice [20], [26], [28], [29], [30]. Here, ADRB3 is linked to obesity disorder.